U.S. Markets closed

Aethlon Medical, Inc. (AEMD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.6600+0.0200 (+0.76%)
At close: 4:00PM EST

2.6200 -0.04 (-1.50%)
After hours: 7:16PM EST

Full screen
Loading interactive chart...
  • Aethlon Medical Expands Leadership Team with Appointment of Chief Business Officer and Chief Medical Officer
    PR Newswire

    Aethlon Medical Expands Leadership Team with Appointment of Chief Business Officer and Chief Medical Officer

    Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, today announced the expansion of its executive team with two key appointments: Guy Cipriani as Senior Vice President and Chief Business Officer, and Steven LaRosa, M.D., as Chief Medical Officer. In his new role, Mr. Cipriani will oversee business development and partnerships, while also contributing to fundraising and corporate development. Dr. LaRosa will be responsible for the clinical development of Aethlon's Hemopurifier®, including leading clinical operations and regulatory strategy.

  • Aethlon Medical to Present at the H.C. Wainwright BioConnect 2021 Conference
    PR Newswire

    Aethlon Medical to Present at the H.C. Wainwright BioConnect 2021 Conference

    Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, today announced that the company will participate in the virtual H.C. Wainwright BioConnect 2021 Conference to be held Jan. 11-14, 2021.

  • Aethlon Medical Announces First Patient Treated in First-in-Human Clinical Trial of HEMOPURIFIER® in Head and Neck Cancer
    PR Newswire

    Aethlon Medical Announces First Patient Treated in First-in-Human Clinical Trial of HEMOPURIFIER® in Head and Neck Cancer

    Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, announced today that the first patient has been treated in the Company's first-in-human Early Feasibility Study (EFS) evaluating the HEMOPURIFIER® in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. The study is enrolling patients at UPMC Hillman Cancer Center in Pittsburgh, PA. (Hemopurifier Plus Pembrolizumab in Head and Neck Cancer - Full Text View - ClinicalTrials.gov).